Attached files
| file | filename |
|---|---|
| EX-10.2 - Immune Therapeutics, Inc. | ex10-2.htm |
| EX-10.1 - Immune Therapeutics, Inc. | ex10-1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
| July 22, 2020 |
| Date of Report (Date of earliest event reported) |
| Immune Therapeutics, Inc. |
| (Exact name of registrant as specified in its charter) |
| Florida | 000-54933 | 59-3226705 | ||
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No. |
| 2431 Aloma Ave, Suite 124, Winter Park, FL | 32792 | |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code 888-613-8802
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| [ ] | Written communications pursuant to Rule 425 under Securities Act (17 CFR 230.425) |
| [ ] | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| [ ] | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| [ ] | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol | Name of exchange on which registered | ||
| Common stock $0.0001 per share | IMUN | OTC Markets |
Emerging growth company [X]
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
On July 22, 2020, director Kevin J. Phelps, interim president and CEO of Immune Therapeutics, Inc. (“Immune” or the “Company”) entered into a three-year executive employment agreement (the “Agreement”) with the Company to serve as president and CEO. This agreement was formally approved by the Company’s Board as of July 24, 2020 with Mr. Phelps abstaining. While fully effective, the parties may expand and restate the Agreement within thirty days.
| Exhibit No. | Description | |
10.1 |
Short-form Executive Employment Agreement dated July 22, 2020 | |
| 10.2 | Board Resolution dated July 24, 2020 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| IMMUNE THERAPEUTICS, INC. | |||
| Date: July 27, 2020 | By: | /s/ Roscoe M. Moore | |
| Dr. Roscoe M. Moore Jr., Chairman | |||